Prime Minister Narendra Modi's mention of 'green jobs' in his Independence Day speech this year re-emphasised his commitment to achieving the Net Zero emissions target by 2070. The question is how will India, arguably the world's third-largest greenhouse gas emitter, achieve this target, with even the goal of limiting global warming to an increase of no more than 1.5 degrees Celsius (1.5°C) above pre-industrial levels, looking like a steep challenge?
As the market regulator, the Securities and Exchange Board of India (SEBI) has added heft to the net zero target, by expanding the disclosures that listed entities need to make related to Environmental, Social and Governance (ESG) factors.
A SEBI circular dated July 12, 2023 mandates that the top 150 listed entities (by market cap) had to undertake reasonable assurance of Business Responsibility and Sustainability Reporting (BRSR) Core from FY23-24, and this will extend to the top 1000 listed entities by FY26-27. The circular also requires the top 250 listed companies by market cap to disclose BRSR Core information for their value chain in their Annual Reports for FY24-25 on a comply-or-explain basis.
As Ramesh Swaminathan, Executive Director, Global CFO and Head of Corporate Affairs, Lupin points out, the pharmaindustry's contribution to the climate crisis comes from its 4.4 per cent share of global CO2 emissions. Although this percentage is lower than that of other industries, without action, emissions are expected to rise. Thus, he points out that the pharma industry has a unique responsibility to take action and promote sustainability. While it needs to reduce its greenhouse gas (GHG) emissions through net-zero strategies, it also needs to address the adverse health effects of the climate crisis by providing affordable medicines.
This story is from the September 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the September 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
CILICANT is changing the way we think about active packaging
Team CILICANT shared insights into their journey of innovation, customer-centric solutions, and their ambitious plans for global expansion. In this engaging dialogue, the team also shed light on their unique value proposition, recent achievements, and strategies for adapting to a rapidly evolving pharma landscape, in an exclusive conversation with Express Pharma
KPMG 2024 Life Sciences CEO Outlook
This recent KPMG report explores the perspectives and priorities of life sciences CEOs amid economic and geopolitical uncertainty, focusing on growth strategies, digital transformation, ESG goals, and workforce challenges. Excerpts from the report
Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends
Industry experts highlight the evolving dynamics, regulatory needs, and personalised solutions driving the nutra market ahead of 2025
We aim to strengthen our presence in Asian and MENA regions, with particular emphasis on India
Matthias Poslovski, Chief Sales Officer, Optima Pharma, speaks on the company's evolution and shares insights on emerging trends like personalised medicine, digitalisation, and Al-driven technologies, while outlining his company's strategies for market expansion, particularly in Asia and MENA, with a focus on the Indian pharma sector, in an exclusive interaction with Lakshmipriya Nair
Sustaining excellence: The evolving role of quality in pharma
In the ever-evolving landscape of the pharma industry, the pursuit of quality remains a cornerstone of success. As stringent regulatory frameworks, rising patient expectations, and the increasing pace of innovation, transforms the pharma industry, the definition of quality is also evolving. From ensuring compliance with global standards to embracing cutting-edge technologies like Al-driven quality control, the industry is navigating a paradigm shift in how it approaches product integrity, safety, and efficacy. In this New Year issue, pharma experts explore how crucial it is to foster a culture of quality across organisations and deliver better healthcare outcomes
Revolutionising pharma the adaptive way
Adaptive manufacturing offers better performance, efficient management of diverse products, a reduced machine footprint, faster batch changes, and enhanced operational sustainability
Trends 2025: Redefining the pharma supply chain
Saurabh Gupta, Global Head of Supply Chain, Lupin highlights trends such as Al integration, digitalisation and sustainability that are shaping a future-ready supply chain
Growth mantras for 2025: Innovation, Partnerships, Sustainability
Innovation, synergy, and sustainability are shaping the trajectory of India's pharma sector, unlocking new frontiers of growth, inform industry stakeholders
Will Epygen's biosimilars bets pay off?
Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a conversation with Viveka Roychowdhury, he analyses the journey so far, spanning pandemic preparedness projects like protein-based vaccines, building up pipeline revenue streams in diabetes, oncology, immunology and cardiovascular biosimilars, and his strategies to scale up and expand to other therapeutics like anti-obesity drugs
Innovation, partnerships and best practices: Priorities for biopharma in 2025
Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth
